In recent commentaries, possible mechanisms of action of metformin which may have conflicting effects in COVID-19 has been proposed [@b0005], [@b0010], [@b0015]. In this commentary, a possible role of metformin in COVID-19 on neutrophils, the first line of defense against microbial, fungal and viral infections is proposed. Although a controlled neutrophilic response is needed to combat infection, uncontrolled neutrophilic response can be deleterious [@b0020].

A longitudinal study in 548 patients from China reported that a progressive increase in neutrophil count or neutrophil lymphocyte ratio was associated with a fatal outcome [@b0025] and a similar report have been published from Poland [@b0030]. In an autopsy study of COVID-19 patients, neutrophil infiltration in pulmonary capillaries, extravasation of neutrophils into the alveolar space, and neutrophilic mucositis has been reported [@b0035].

Neutrophil extracellular traps (NETs) first described in 2004 [@b0040], are extracellular chromatic webs released from neutrophils and contains deoxyribonucleic acid (DNA), histones, microbicidal proteins, (neutrophil elastase and myeloperoxidase) [@b0045]. Recent reports have shown that that sera from patients with COVID-19 have elevated levels of NETS such as cell-free DNA, myeloperoxidase (MPO)-DNA, and citrullinated histone H3 (Cit-H3), highly specific markers of NETs and these were associated with markers of inflammation [@b0050]. If controlled, NETs are beneficial in the host defence against pathogens [@b0050]. However, if excessive NET formation occurs it has the potential to trigger inflammatory cascade that has been associated with cytokine storm [@b0050], ARDS [@b0055] and microthrombosis [@b0060] all causes of fatality in COVID-19.

Metformin has been shown to reduce neutrophil count in polycystic ovarian disease [@b0065] and reduce neutrophil lymphocyte ratio in patients with diabetes [@b0070]. It has also been shown to ameliorate NETosis in patients with diabetes [@b0075] and pre-diabetes independent of glucose control [@b0080]. Metformin has been associated with a decrease in neutrophil gelatinase-associated lipocalin (NGAL), an acute phase protein released by neutrophils and is known to be elevated in patients with diabetes [@b0085]. Animal studies have shown that metformin reduces post myocardial infarction injuries by reducing cardiac remodelling and myocardial neutrophil activity [@b0090]. Metformin has also been seen to reduce neutrophil and macrophage infiltration in hyperoxia induced lung injury in neonatal rats [@b0095].

While beneficial mechanistic links through neutrophils can be suggested with the use of metformin, it is important to realise that a relatively high rate of mortality in patients with co-existing diabetes has been reported in COVID-19 [@b0100]. A vast majority of these patients would have been on metformin. Until we have real world data on the effects of metformin use in COVID-19 patients with diabetes, no conclusive judgement with regards to its overall usefulness, neutral or detrimental effects can be made.
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